YZ3 Stock Overview
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
CASI Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.54 |
52 Week High | US$4.60 |
52 Week Low | US$1.37 |
Beta | 0.44 |
1 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | -44.00% |
3 Year Change | -93.42% |
5 Year Change | -96.84% |
Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Shareholder Returns
YZ3 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -5.9% | -1.7% |
1Y | -44.0% | -21.4% | -0.2% |
Return vs Industry: YZ3 underperformed the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: YZ3 underperformed the German Market which returned 6.3% over the past year.
Price Volatility
YZ3 volatility | |
---|---|
YZ3 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YZ3 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine YZ3's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 224 | Wei-Wu He | www.casipharmaceuticals.com |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company’s other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc
CASI Pharmaceuticals, Inc. Fundamentals Summary
YZ3 fundamental statistics | |
---|---|
Market cap | €25.94m |
Earnings (TTM) | -€35.13m |
Revenue (TTM) | €38.75m |
0.7x
P/S Ratio-0.7x
P/E RatioIs YZ3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
YZ3 income statement (TTM) | |
---|---|
Revenue | US$42.39m |
Cost of Revenue | US$15.45m |
Gross Profit | US$26.95m |
Other Expenses | US$65.37m |
Earnings | -US$38.43m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.88 |
Gross Margin | 63.56% |
Net Profit Margin | -90.65% |
Debt/Equity Ratio | 0% |
How did YZ3 perform over the long term?
See historical performance and comparison